Drug intelligence / Profile preview

MK-5478

Development stage: Phase 1
Lead developer: Merck
Modality: Small Molecules
Administration: Oral

Overview

MK-5478 is an orally active small molecule compound developed by Merck for the treatment of hypertension and other cardiovascular diseases. It was investigated in clinical trials as a potential antihypertensive agent, with a completed phase I trial in Belgium. The drug's mechanism of action has not been explicitly detailed in public sources, but it is positioned as a novel therapy for hypertension and related cardiovascular conditions[1][2][3]. Its current global development status is pending.

Targets

AGTR1 (Angiotensin II Type-1 receptor)

Beyond the preview

Go deeper on MK-5478.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MK-5478.

Explore the full profile